Affiliation:
1. Orion Corporation, Orion Pharma, Espoo, Finland
2. Bayer AG, Berlin, Germany
Abstract
Background:
Saini et al. recently investigated the pharmacokinetics of darolutamide
and its diastereomers in vitro and in vivo in Balb/c mice, reporting higher levels of (S,S)-darolutamide
than (S,R)-darolutamide following intravenous or oral dosing, and interconversion of
(S,R)-darolutamide to (S,S)-darolutamide.
Objective:
To present our in vitro and in vivo studies of darolutamide pharmacokinetics in mice,
which contrast with the findings of Saini et al.
Methods:
Nude male Balb/c mice were orally dosed for 7 days with 25, 50, or 100 mg/kg of darolutamide
twice daily. Pharmacokinetic parameters in plasma and tissue samples were assessed by
liquid chromatography-tandem mass spectrometry. Metabolism and interconversion of darolutamide
and its diastereomers were investigated in cryopreserved Balb/c mouse hepatocytes. Protein
binding was determined in plasma samples by equilibrium dialysis.
Results :
On day 7, Cmaxwas reached 30 min after the last dose. Rapid formation and greater exposure
of keto-darolutamide versus darolutamide were observed. Plasma exposure of (S,R)-darolutamide
was 3-5-fold higher than that of (S,S)-darolutamide. The fraction of unbound keto-darolutamide
was almost 6-fold lower than for darolutamide.
Conclusion:
The darolutamide diastereomer ratio changes upon administration in mice and other
species due to interconversion through keto-darolutamide. This is not considered clinically relevant
since both diastereomers and keto- darolutamide are pharmacologically similar in vitro. Based on
the high protein binding of keto-darolutamide, its contribution in vivo in humans is considered low.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Biochemistry (medical),Clinical Biochemistry,Pharmaceutical Science
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献